WO2019011875A1 - Quantification d'oligonucleotides antisens (asos) - Google Patents

Quantification d'oligonucleotides antisens (asos) Download PDF

Info

Publication number
WO2019011875A1
WO2019011875A1 PCT/EP2018/068572 EP2018068572W WO2019011875A1 WO 2019011875 A1 WO2019011875 A1 WO 2019011875A1 EP 2018068572 W EP2018068572 W EP 2018068572W WO 2019011875 A1 WO2019011875 A1 WO 2019011875A1
Authority
WO
WIPO (PCT)
Prior art keywords
ligation
partner
oligonucleotide
analyte
accessible
Prior art date
Application number
PCT/EP2018/068572
Other languages
English (en)
Inventor
Jörg KRUMMHEUER
Peter Mouritzen
Original Assignee
Qiagen Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qiagen Gmbh filed Critical Qiagen Gmbh
Publication of WO2019011875A1 publication Critical patent/WO2019011875A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification

Definitions

  • the present invention relates to methods and kits for determining oligonucleotide analytes in a sample, more particularly for quantitatively determining an antisense oligonucleotide analyte in a biological sample.
  • Antisense oligonucleotides are synthetic single-stranded nucleic acid molecules that are capable to bind to complementary target RNA molecules by hybridization. Thereby, antisense oligonucleotides interfere with gene expression.
  • Antisense oligonucleotides have been developed as drugs for diseases such as cancers including lung cancer, colorectal carcinoma, pancreatic carcinoma, malignant glioma and malignant melanoma, diabetes, amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, spinal muscular atrophy, asthma, arthritis and other diseases. Meanwhile, several antisense drugs have been approved by the US Food and Drug Administration.
  • diseases such as cancers including lung cancer, colorectal carcinoma, pancreatic carcinoma, malignant glioma and malignant melanoma, diabetes, amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, spinal muscular atrophy, asthma, arthritis and other diseases. Meanwhile, several antisense drugs have been approved by the US Food and Drug Administration.
  • An oligonucleotide analyte hybridizes to the immobilized hairpin resulting in the formation of an immobilized nicked double strand comprising an intramolecular and an intermolecular portion. Determination of the analyte is possible by several methods.
  • US 6,355,438 B1 discloses a method for detecting or quantitating an oligonucleotide analyte, wherein said oligonucleotide comprises at least one modification.
  • the method comprises forming a hybrid of the modified oligonucleotide with a probe, wherein the probe comprises a region at one end thereof which does not hybridize to the modified oligonucleotide and subsequently incorporating a detectable label into the modified oligonucleotide opposite to the non-hybridizing region of the probe by means of a ligation reaction between the oligonucleotide analyte with a labelled detection probe and detecting the label.
  • US 7,306,904 B2 discloses an assay for detecting and/or quantitating one or several analytes in solution by a proximity probe, comprising an analyte binding moiety coupled to an oligonucleotide with a free 5'-end and a further proximity probe comprising a further analyte binding moiety coupled to an oligonucleotide with a free 3'-end.
  • the oligonucleotides from different proximity probes are capable of interaction with each other, e.g. by ligation, when bound via the binding moieties to the analyte.
  • the ligation product may be detected by nucleic acid amplification.
  • the present invention provides novel methods and kits which allow quantitative determination of oligonucleotide analytes, e.g. antisense oligonucleotides, through a ligation/amplification reaction combining the sensitivity of an amplification with the specificity of a ligase reaction.
  • the oligonucleotide analyte serves as a junction or splint bridging two complementary nucleic acid sequence portions present in one or more ligation partner oligonucleotides by sequence-dependent Watson-Crick base pairing.
  • Hybridization of the oligonucleotide analyte with the two complementary nucleic acid sequence portions of the ligation partner(s) generates a contiguous sequence of the two complementary sequence portions interrupted by a nick.
  • the respective ends of the sequence portions have ligation-accessible 5'- and 3'-ends allowing that the nick is converted to a covalent bond, e.g. a phosphodiester bond by an enzymatic ligation.
  • the product of the ligation reaction i.e. ligation product, comprises the two complementary sequence portions of the ligation partner(s) covalently linked to each other.
  • the amount of ligation product correlates with the amount of oligonucleotide analyte present in the sample.
  • the ligation product may serve as an amplification template allowing a quantitative determination of the analyte by nucleic acid amplification, e.g. by real time quantitative PCR (qPCR).
  • the present invention relates to a method for determining an oligonucleotide analyte in a sample, comprising
  • the at least one ligation partner is an oligonucleotide capable of hybridizing with the oligonucleotide analyte
  • the present invention relates to a kit for determining an oligonucleotide analyte in a sample comprising:
  • the oligonucleotide analyte is capable of hybridizing with the at least one ligation partner by bridging together two ends of the at least one ligation partner wherein a contiguous sequence of nucleotides interrupted by a nick between a ligation-accessible 3'-end and a ligation-accessible 5'-end of the at least one ligation partner is generated,
  • the present invention relates to a method for determining an oligonucleotide analyte in a sample comprising
  • the at least one ligation partner is an oligonucleotide capable of hybridizing with the oligonucleotide analyte
  • the oligonucleotide analyte is an antisense oligonucleotide, e.g. an antisense oligonucleotide comprising at least one modified nucleoside building block, particularly a locked nucleoside building block, and/or at least one modified internucleosidic linkage, particularly a phosphorothioate linkage.
  • the invention relates to a method for determining an oligonucleotide analyte in a sample, comprising
  • the at least one ligation partner is an oligonucleotide capable of hybridizing with the oligonucleotide analyte
  • the method comprises adding to the sample a first ligation partner and a second ligation partner, wherein the first ligation partner comprises a 3'-terminal sequence portion with a ligation- accessible 3'-end which hybridizes with a 3'-terminal sequence portion of the oligonucleotide analyte and the second ligation partner comprises a 5'-terminal sequence portion with a ligation- accessible 5'-end which hybridizes with a 5'-terminal sequence portion of the oligonucleotide analyte thereby forming a linear contiguous sequence interrupted by a nick, and
  • first ligation partner having a ligation-accessible 3'-end comprises at least one modified nucleoside building block, particularly at least one locked nucleoside building block
  • second ligation partner having a ligation-accessible 5'-end does not comprise a modified nucleoside building block, particularly a locked nucleoside building block
  • the invention relates to a method for determining an oligonucleotide analyte in a sample, comprising
  • the at least one ligation partner is an oligonucleotide capable of hybridizing with the oligonucleotide analyte
  • step (iii) wherein at least one stacking partner of the oligonucleotide analyte is added to the sample before step (iii), wherein the stacking partner is an oligonucleotide which hybridizes with the at least one ligation partner adjacent to the 3'-end and/or the 5'-end of the oligonucleotide analyte.
  • the method and kit of the invention are suitable for determining an oligonucleotide analyte in a sample.
  • the term "determining" comprises qualitatively determining the presence of the oligonucleotide analyte and/or quantitatively determining the amount of the oligonucleotide analyte in the sample.
  • the present invention comprises a quantitative determination.
  • oligonucleotide analyte relates to a single-stranded oligonucleotide which may have a length of about 8 to about 50 nucleotides, preferably about 10 to about 25 nucleotides.
  • the oligonucleotide analyte may be a DNA and/or RNA oligonucleotide optionally comprising at least one modified nucleosidic building block and/or at least one modified internucleosidic linkage between two nucleoside building blocks.
  • the oligonucleotide analyte is an antisense oligonucleotide.
  • antisense oligonucleotide relates in particular to oligodeoxyribonucleotides which may comprise at least one modified nucleoside building block and/or at least one modified internucleosidic linkage. The presence of modified nucleoside building blocks and/or modified internucleosidic linkages increases the stability of antisense oligonucleotides under physiological conditions. Thus, pharmaceutical antisense oligonucleotides usually comprise such modifications.
  • modified nucleoside building blocks are base-modified building blocks comprising a non-naturally occurring nucleobase, e.g. 5-methyl cytosine, and sugar-modified building blocks comprising a non-naturally occurring sugar moiety, e.g. a 2'-modified sugar moiety and/or a locked sugar moiety.
  • sugar-modified building blocks comprising a non-naturally occurring sugar moiety, e.g. a 2'-modified sugar moiety and/or a locked sugar moiety.
  • 2'-modified nucleoside building blocks are 2'-methoxy, 2'-F and/or 2'-0-ethoxymethyl building blocks.
  • Locked nucleoside building blocks contain a bridge between two atoms of the pentose sugar, e.g. the deoxyribose sugar.
  • a bridge is formed between the 2'-C atom and the 4'-C atom of the sugar, e.g. a 2-atom or 3-atom bridge, preferably comprising at least one heteroatom such as O, N or S.
  • Preferred are bridges having the structure 2'-0-CH 2 -4' or 2'-0-CH 2 -CH 2 -4', wherein at least one H atom may be substituted, e.g. by C C 3 alkyi, CrC 3 alkoxy or CrC 3 alkyi, or C-1 -C3 alkoxy groups, e.g. a 2'-0-CH(CH 3 )-4' bridge.
  • a bridge having the structure 2'-0-CH 2 -4' is especially preferred.
  • the internucleosidic linkages in the oligonucleotide analyte may be phosphodiester bonds and/or modified internucleosidic linkages such as phoshorothioate linkages.
  • antisense oligonucleotides comprise a plurality of modified nucleoside building blocks, e.g. locked nucleoside building blocks and/or 2'- modified building blocks and a plurality of modified internucleosidic linkages.
  • Modified nucleoside building blocks and/or modified nucleosidic linkages may be present at any position of the antisense oligonucleotide.
  • the respective molecules are designated as gapmer, blockmer, headmer, tailmer, mixmer or totalmer.
  • the present invention is applicable to all of these molecules since it does not require the presence of ligation-accessible 5'- and/or 3'-ends in the oligonucleotide analyte.
  • the method of the invention is used for determining an oligonucleotide analyte in a sample.
  • the sample may be a biological sample, e.g. a cell culture, tissue and/or body fluid sample such as a tissue biopsy, blood, serum, plasma, urine sample, etc.
  • the sample may be pretreated, e.g. by lysis of cellular components according to standard methods.
  • the determination of the oligonucleotide analyte may be carried out directly in the lysed sample or in a fraction thereof.
  • the oligonucleotide analyte is usually present together with endogenous nucleic acid molecules including genomic DNA and/or RNA molecules which may comprise the nucleotide sequence of the oligonucleotide analyte and/or its complement thereof.
  • the method of the invention allows determination of the oligonucleotide analyte in the presence of endogenous nucleic acid molecules.
  • the method allows determination of the oligonucleotide in a sample without previous separation of endogenous nucleic acid molecules present in the sample, particularly without previous separation of endogenous RNA molecules present in the sample.
  • the method comprises determination of the oligonucleotide in an RNA-containing sample fraction obtained from a biological sample.
  • Step (i) of the method of the invention comprises adding at least one ligation partner of the oligonucleotide analyte to the sample.
  • ligation partner refers to an oligonucleotide comprising at least one sequence portion complementary to the nucleotide sequence of the analyte.
  • the ligation partner comprises a ligation-accessible 5'- and/or 3'-end, i.e. an end which is accessible to ligation wherein a covalent bond is formed.
  • the invention involves the use of a first ligation partner and a second ligation partner which are both oligonucleotides capable of hybridzing with the oligonucleotide analyte.
  • the first ligation partner comprises a 3'-terminal sequence portion with a ligation-accessible 3'-end which hybridizes with a 3'-terminal sequence portion of the oligonucleotide analyte.
  • the second ligation partner comprises a 5'-terminal sequence portion with a ligation-accessible 5'-end which hybridizes with a 5'-terminal sequence portion of the oligonucleotide analyte.
  • a double-stranded hybridization product comprising the analyte and the first and second ligation partners is formed in step (ii).
  • a first strand of the hybridization product comprises the oligonucleotide analyte and the second strand of the hybridization product comprises the first and the second ligation partner. Since the first and second ligation partners comprise sequence portions which do not hybridize with the oligonucleotide analyte, the second strand extends on both sides beyond the ends of the first strand.
  • the nucleotide sequences of the first and second ligation partners are selected such that they, when hybridized to the oligonucleotide analyte, form a linear contiguous sequence of nucleotides with a nick between the ligation-accessible 3'-end of the first ligation partner and the ligation-accessible 5'-end of the second ligation partner.
  • a further embodiment of the invention involves the use of only one ligation partner.
  • the ligation partner comprises a 3'-terminal sequence portion with a ligation-accessible 3'-end which hybridizes with a 3'-terminal sequence portion of the oligonucleotide analyte and a 5'-terminal sequence with a ligation-accessible 5'-end which hybridizes with a 5'-terminal sequence portion of the oligonucleotide analyte thereby forming a circular contiguous sequence interrupted by a nick.
  • the ligation partner forms a double-stranded hybridization product with the analyte.
  • a first strand of the hybridization product comprises the oligonucleotide analyte and the second strand of the hybridization product, which is circular, comprises the ligation partner.
  • the nucleotide sequence of the ligation partner is selected such that, when hybridized to the oligonucleotide analyte, forms a contiguous sequence of nucleotides with a nick between its ligation-accessible 3'-end and its ligation-accessible 5'-end.
  • the ligation partner(s) used according to the present invention are oligonucleotides having at least one sequence portion with a suitable length for hybridizing with a portion of the oligonucleotide analyte and an additional sequence portion, e.g. for hybridization with a complementary nucleotide sequence different from the oligonucleotide analyte, e.g. for hybridization with a primer.
  • the length of the respective oligonucleotides is usually at least 15 nucleotides and up to e.g. 200 nucleotides, particularly from about 25 to about 60 nucleotides. In embodiments which involve the use of a single ligation partner, its length is usually at least 40 nucleotides and up to e.g. 250 nucleotides, particularly about 50 to about 150 nucleotides.
  • the ligation partner(s) may comprise deoxyribonucleoside building blocks and optionally at least one modified nucleoside building block, particularly at least one locked nucleoside building block as described above. Further, the ligation partner (s) may comprise internucleosidic linkages selected from phosphodiester linkages and optionally at least one modified internucleosidic linkage such as a phosphorothioate linkage.
  • the first ligation partner having a ligation-accessible 3'-end comprises at least one modified nucleoside building block, particularly at least one locked nucleoside building block
  • the second ligation partner having a ligation-accessible 5'-end does not comprise a modified nucleoside building block, particularly a locked nucleoside building block.
  • the first ligation partner having a ligation-accessible 3'-end may comprise two modified nucleoside building blocks, particularly locked nucleoside building blocks.
  • the modified nucleoside building blocks may be located in a sequence portion complementary to the nucleoside sequence of the oligonucleotide analyte. Further, the modified nucleoside building blocks may be separated by one or more non-modified nucleoside building blocks, particularly by four non-modified nucleoside building blocks.
  • the ligation partner(s) may comprise labelling and/or binding moieties.
  • labelling moieties are e.g. fluorescent or luminescent groups.
  • binding moieties are e.g. solid phase binding moieties which allow binding to a complementary binding partner which may be immobilized on solid phase, e.g. a bead, in particular a magnetic bead.
  • An example of a suitable binding moiety is biotin which may be immobilized to a solid phase coated with streptavidin. The presence of binding moieties allows capture of reactants and separation from other sample constituents.
  • test format of the method of the present invention may involve in some embodiments that at least steps (i) and (ii), or steps (i), (ii) and (iii) are carried out under conditions wherein the oligonucleotide analyte and the at least one ligation partners are in solution.
  • the method involves an immobilization of reactants on a solid phase and separation of non- immobilized sample constituents.
  • Step (iii) involves the closing of the nick between a ligation-accessible 3'-end and a ligation-accessible 5'-end of the at least one ligation partner by a ligation reaction, wherein a covalent bond is generated.
  • the ligation-accessible 3'-end may be a free 3'-OH group at the 3'-end or a group which under test conditions may be converted to free 3'-OH group.
  • the ligation-accessible 5'-end is selected such that it can be ligated to the ligation-accessible 3'-end.
  • the ligation-accessible 5'-end comprises a phosphate group or a group which under test conditions may be converted to a phosphate group.
  • a covalent bond preferably a phosphodiester bond
  • the ligation reaction may be an enzymatic ligation catalyzed by a ligase enzyme capable of covalently joining a ligation-accessible 3'-end and a ligation-accessible 5'-end, e.g. a DNA ligase.
  • suitable ligase enzymes are e.g. particularly selected from Taq DNA ligase, T4 DNA ligase, splint R ligase, E. coli DNA ligase, etc.
  • the ligation reaction is carried out in a suitable ligation buffer at a temperature at which the respective ligase is active and double-stranded hybrids of ligation partner(s) and oligonucleotide analyte may be formed, e.g. a temperature at about 25°C to 40°C, in particular about 38°C. In certain embodiments, the temperature may vary during the course of the ligation reaction.
  • the ligase is inactivated, e.g. by increasing the temperature to 50°C or higher, e.g. 65°C for a period of time which is sufficient to inactivate the respective ligase.
  • At least one stacking partner of the oligonucleotide analyte is added to the sample before step (iii).
  • the stacking partner is an oligonucleotide which hybridizes with the at least one ligation partner adjacent to the 3'-end or the 5'-end of the oligonucleotide analyte.
  • one stacking partner is added which hybridizes with the at least one ligation partner adjacent to the 3'-end of the oligonucleotide.
  • one stacking partner is added which hybridizes with the at least one ligation partner adjacent to the 5'-end of the oligonucleotide analyte.
  • two stacking partners are added, one of which hybridizes adjacent to the 3'-end and the other one adjacent to the 5'- end of the oligonucleotide analyte.
  • the hybridization product of the oligonucleotide analyte and the at least one ligation partner generated in step (ii) additionally comprises the at least one stacking partner, i.e. a further oligonucleotide hybridized to the at least one ligation partner at a position adjacent to the 3'-end and/or the 5'-end of the oligonucleotide analyte.
  • the stacking partner can form a contiguous sequence with the oligonucleotide analyte which is interrupted by a nick between the 3'-end of the stacking partner and the 5'-end of the oligonucleotide analyte or between the 5'-end of the stacking partner and the 3'-end of the oligonucleotide analyte.
  • the method of the invention does not involve a closing of the nick between the stacking partner and the oligonucleotide analyte in step (iii). This can be achieved by providing stacking partners which do not provide ligase- accessible combinations of 5'- and 3'-ends with the oligonucleotide analyte.
  • the stacking partner may be an oligonucleotide having a length of about 6 to about 50 nucleotides. It may optionally contain modified nucleoside building blocks, e.g. locked nucleoside building blocks and/or modified internucleosidic linkages, e.g. phosphorothioate linkages.
  • modified nucleoside building blocks e.g. locked nucleoside building blocks and/or modified internucleosidic linkages, e.g. phosphorothioate linkages.
  • the stacking partners are selected such that they do not interfere with the subsequent amplification reaction using the ligation product as template.
  • the stacking partner may be a short oligonucleotide, e.g. with a length of about 6 to about 12 nucleotides, such that a double-stranded hybrid comprising the stacking partner with the ligation partner has a melting point ranking between the melting point of a hybrid of the oligonucleotide analyte and the ligation partner and the melting temperature of a hybrid of a primer used the subsequent amplification and the ligation partner.
  • the stacking partner may be identical with one of the detection primers.
  • the double-stranded hybridization product comprising oligonucleotide analyte and the at least one ligation partner is subjected to a nucleic acid amplification reaction.
  • the amplification reaction is carried out under conditions which require the presence of the ligation product of step (iii) as a template.
  • the amplification reaction will allow qualitative and quantitative determination of the oligonucleotide analyte.
  • the nucleic acid amplification reaction is real time quantitative PCR (qPCR) involving the use of primers binding to sequence portions of the at least one ligation partner which are not hybridized with the oligonucleotide analyte and carrying out successive amplification cycles involving primer elongation using a suitable DNA polymerase, in particular a thermostable DNA polymerase such as Taq DNA polymerase or variants thereof.
  • qPCR real time quantitative PCR
  • the primers are oligonucleotides capable of hybridization with the ligation product generated by the ligation reaction in step (iii).
  • the primers are selected such that they hybridize with sequence portions of the ligation partner(s) which are not complementary to the oligonucleotide analyte.
  • the method of the invention allows a relative or absolute quantitative determination of the oligonucleotide analyte in the sample based on the amount of ligation product present after step (iii).
  • the reaction can be calibrated by using controls containing known amounts of the oligonucleotide analyte thereby allowing an absolute quantitative determination.
  • nucleic acid amplification comprises NASBA, rolling circle amplification, e.g. in embodiments where a single ligation partner is used. These methods also allow a quantitative determination of the oligoanalyte based on the amount of ligation product initially present after step (iii) which correlates with the amount of oligonucleotide analyte in the sample.
  • the method of the invention can be carried out in a single combined reaction wherein the reactants of the ligation reaction, i.e. the at least one ligation partner and the ligase and optionally at least one stacking partner may be added to the sample at the same stage as the reactants of the nucleic acid amplification reaction, i.e. at least one primer, amplification enzyme, e.g. a DNA polymerase and nucleoside triphosphates.
  • the inactivation of the ligase may then be the activation step of the nucleic acid amplification.
  • the reactants of the nucleic acid amplification may be added to the sample after the ligation has been completed.
  • the present invention relates to a kit for determining an oligonucleotide analyte, in particular an antisense oligonucleotide, in a sample.
  • the kit optionally comprises the oligonucleotide analyte and at least one ligation partner adapted to the determination of the specific analyte as described above.
  • the kit may comprise optional components such as a ligase and/or at least one stacking partner and/or an instruction manual.
  • the kit may comprise the components used for the amplification reaction, in particular at least one primer, particularly a primer pair which hybridizes to the ligation product for use in the amplification reaction.
  • the kit is particularly suitable for use in a method as described above.
  • Still a further aspect of the present invention relates to a method for directly determining an oligonucleotide analyte, particularly an antisense oligonucleotide, in a small nucleic acid, e.g. a RNA-containing fraction, such as a small RNA-containing fraction, of a biological sample, e.g. a micro-RNA- containing fraction which may be obtained with a suitable isolation protocol, e.g. the miRNeasy protocol from Qiagen.
  • the oligonucleotide analyte may be determined without prior separation of other sample constituents, e.g. endogenous nucleic acid molecules present in the sample.
  • the determination may be carried out according to any suitable method, e.g. methods involving ligation and/or amplification reactions.
  • the oligonucleotide analyte may be determined by combined ligation/amplification reaction, e.g. in a single combined reaction, particularly by the method as described above in detail.
  • Figure legends Figure 1 shows an embodiment of the invention involving determination of an antisense oligonucleotide (ASO) with two ligation partner oligonucleotides 'a' and 'b'.
  • ASO antisense oligonucleotide
  • the ligation partner oligonucleotides 'a' and 'b' hybridize to the antisense oligonucleotide (ASO).
  • ASO antisense oligonucleotide
  • the ASO acts as a junction for bridging together the ligation partners 'a' and 'b' which form a contiguous sequence interrupted by a nick.
  • the first (5') ligation partner 'a' has a ligation-accessible 3'-end, e.g. a 3'-OH group.
  • the second (3') ligation partner 'b' has a ligation-accessible 5'-end which may be phosphorylated (P in circle) to enable ligation between the partners 'a' and 'b'.
  • One of the ligation partners e.g. the ligation partner 'a' can have a labelling or a binding group, e.g. a binding group to allow binding to a solid phase, e.g. a bead (B in circle).
  • B After closing the nick between ligation partners 'a' and 'b' by means of a ligation reaction, the resulting ligation product is subjected to an amplification reaction.
  • the ligation product is used as a template in a PCR reaction involving the addition of two suitable primers designated as FWD-DS and REV-DS.
  • Figure 2 shows the quantitative determination of an oligonucleotide analyte with 5'- and 3'-ligation partner oligonucleotides.
  • the resulting number of quantification cycles (Cq) was found to be dependent from the amount of analyte present in the sample.
  • the individual graphs are dilution curves based on Cq values for samples spiked with ASO GPanti-miR-205 in concentrations from 10 nM to 1 pM comparing ligations of a 5' partner (a) without LNA (blue and red curve) and a 5'-ligation partner (a) with LNA (purple and green curve), while the 3'-ligation partner contains either DNA (blue and green curves) or LNA (purple and red curve).
  • Figure 3 shows the difference in Cq values (ACQ) for reactions carried out in the presence or absence of a gapmer and a mixmer antisense oligo (ASO) using the different ligase enzymes.
  • Different ligases ligate the substrate with different efficiencies.
  • the difference of Cq values (ACQ) in the PCR ligation assay between 0 and 100 pM ASO anti-miR-205 (mixmer, blue) or a GPanti- miR-205 (gapmer, red) or a negative control m1 -4 gapmer (NC, green) is depicted.
  • Figure 4 shows the detection of an ASO present in an RNA fraction isolated from cells after gymnotic transfection.
  • qPCR Cq values (Y-Axis) are plotted against the gymnotic input amount of the ASO.
  • NC negative control absense of ASO.
  • the ligation PCR assay can detect amounts of 0.001 to 1 ⁇ ASO in a 1 :100 dilution of the ligation reaction.
  • the sample was total RNA directly isolated from cells.
  • DNA ligation partners 'a' and 'b' were used, in the lower panel LNA ligation partners 'a' and 'b' were used.
  • Figure 5 shows a schematic overview of different embodiments wherein additional stacking partners are added prior to ligation.
  • A Use of a reverse amplification primer as stacking partner for ligation partner b.
  • oligonucleotides As stacking partners for ligation partners a and b. These oligos were designated as having a melting temperature ranging between the melting temperature of the ASO and the ligation partner and the melting temperature of the primer and the ligation partner.
  • FIG. 6 shows the effect of the presence of stacking partners.
  • Stacking partners enhance the detection sensitivity of the ASO.
  • the change of Cq (ACQ) in the PCR ligation assay between 0 and 100 pM ASO m1 -4 gapmer (blue) or an unrelated ASO GPanti-miR-205 (gapmer, red) is depicted.
  • the use of the specifically designed stacking oligonucleotides (stacker a/b) or of the reverse primer (revp3opt) as a stacker preannealed to the corresponding ligation partner enhances the detection of the ASO.
  • Oligonucleotide sequences used in the experiments + as prefix denotes LNA; * as suffix denotes phosphorothioate linkage, italics denote the primer binding sites for the PCR primers FWD DS and REV DS.
  • the underlined sequences hybridize to ASO (I or II) but not to the control (NC).
  • /5phos/ denotes a 5' phosphorylation of the oligonucleotide, /iMe-dC/ represents a 5 methyl dC base.
  • Oligonucleotide concentrations below 1 ⁇ were diluted in MS2 (50 ng MS2 in 80 ⁇ H 2 O).
  • the ligation reaction was diluted 1 :80 in the PCR reaction.
  • Quantitative PCR was performed using SYBR green detection ( Exilent mastermix, Exiqon) with 0.3 ⁇ primer FWD DS and Rev-DS.
  • the reaction conditions were 1 x 95°C for 10 min, 45 x 95°C for 10 sec, 60°C for 1 min, 1 .6°C/sec, optical read, with melting curve analysis on a ROCHE LC480 instrument.
  • the data in Figure 2 show the effect on LNA modification of the ligation partners on the ligation and demonstrate that LNA modification in oligo 'a' increases sensitivity of the ligation PCR assay, whereas LNA modification in oligo 'b' decreases sensitivity of the ligation PCR assay under the chosen reaction conditions.
  • the obtained Cq values reflect the input amount of ASO in a linear correlation and demonstrate that the assay allows to quantitatively determine ASO concentration through ligation and subsequent amplification by PCR.
  • the ligase reaction was run at 38°C for 120 min. Then the ligase was inactivated at 65°C for 10 min. 1 ⁇ of the ligation reaction was used per 10 ⁇ PCR reaction. Quantitative PCR was performed using SYBR green detection (2x Exilent Mastermix, Exiqon) with 0.3 ⁇ primers FWD DS and Rev-DS. The reaction conditions were 1 x 95°C for 10 min, 45 x (95°C for 10 sec, 60°C for 1 min, 1 .6°C/sec, optical read), with melting curve analysis on a ROCHE LC480 instrument.
  • the ligation PCR assay detects both mixmer and gapmer ASO in an amount of 100 pM.
  • the ligation partners can be ligated by different ligases. Cq values of anti-miR-205 (I), GPanti-miR-205 (II), m1 -4gapmer (NC) are indicated.
  • the controls "No ASO” were a ligation reaction in absence of ASO and "No ligase" a reaction in the absence of ligase and in the presence of 100 pM ASO.
  • Hela cells were seeded in 24 well plates (1 .38 x10 5 cells/well) and after 24 hrs subjected to gymnosis with 1 ⁇ , 0.1 ⁇ and 0.01 ⁇ ASO, respectively, in DMEM media for 48 hrs. The cells were then washed twice with PBS and the RNA extracted according to the miRNEASY protocol (QIAGEN). The RNA was resuspended in 30 ⁇ H 2 O and 1 ⁇ was subjected to ligation. The ligation mixture was diluted 1 :100 and analysed via PCR.
  • the ligation PCR assay detects mixmer and gapmer ASO from RNA isolated after gymnosis.
  • the ligation partners can be LNA modified.
  • the Cq values of anti-miR-205 (I), GPanti-miR-205 (II), m1 -4gapmer (NC) for three final concentrations (1 ;0.1 ; 0.01 ⁇ ) are shown.
  • the control was a reaction in the absence of ASO.
  • ASOs can be quantified directly from RNA isolated with the QIAGEN miRNEASY kit which preserves the small nucleic acid fraction. Thus no special lysis protocol is required.
  • a linear correlation of Cq values with the amount of ASO allows quantification.
  • the DNA ligation partners 5a and 5b showed linear correlation of Cq values with the input amount of ASO from 0.01 ⁇ to 1 ⁇ .
  • the LNA ligation partner oligonucleotides 5a LNA - 5b showed saturation for gymnotic transfection with 1 ⁇ ASO under the given conditions.
  • the ligation partners with different stacking oligonucleotides. These stacking oligonucleotides hybridize adjacent to the ASO binding part of the ligation partner. When all oligonucleotides are hybridized the stacking oligonucleotide and the ASO will form the first strand with a nick in between and the ligation partners form the second strand with a nick in between.
  • the oligos (100 ⁇ ) were diluted 10 fold in annealing buffer (final cone. 10 mM Tris pH 7.5; 50 mM NaCI; 1 mM EDTA). Then, the oligonucleotides were heated to 95 °C for 2 min then cooled to 25 °C over 45 min and stored at 4 °C.
  • the pre-annealed ligation partners were further diluted to 100 pM and incubated with or without ASO in a touchdown ligation reaction:
  • the affinity of the ASO to hybridize to the ligation partner can be substantially enhanced through pre-hybridization of the ligation partner with a further stacking oligonucleotide.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés et des kits permettant de déterminer des analytes oligonucléotidiques dans un échantillon, et permettant plus particulièrement de déterminer un analyte oligonucléotidique antisens dans un échantillon biologique.
PCT/EP2018/068572 2017-07-11 2018-07-09 Quantification d'oligonucleotides antisens (asos) WO2019011875A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180722.5 2017-07-11
EP17180722 2017-07-11

Publications (1)

Publication Number Publication Date
WO2019011875A1 true WO2019011875A1 (fr) 2019-01-17

Family

ID=59315487

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/068572 WO2019011875A1 (fr) 2017-07-11 2018-07-09 Quantification d'oligonucleotides antisens (asos)

Country Status (1)

Country Link
WO (1) WO2019011875A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3699297A1 (fr) 2019-02-25 2020-08-26 QIAGEN GmbH Procédé permettant de déterminer le niveau d'un d'oligonucléotide antisens

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020679A1 (fr) * 1994-01-26 1995-08-03 Hybridon, Inc. Procede de detection de taux inferieurs a 10-9 d'oligonucleotides dans des fluides biologiques
WO1998004745A1 (fr) * 1996-07-31 1998-02-05 Mount Sinai School Of Medicine Of The City University Of New York Methode d'amplification des acides nucleiques: methode d'amplification avec signal d'hybridation (hsam)
US5770365A (en) 1995-08-25 1998-06-23 Tm Technologies, Inc. Nucleic acid capture moieties
US6355438B1 (en) 1999-11-12 2002-03-12 Isis Pharmaceuticals, Inc. Method for quantitating oligonucleotides
WO2004085667A2 (fr) * 2003-03-24 2004-10-07 International Therapeutics, Inc. Techniques et compositions de detection de presence d'acides nucleiques dans un echantillon
WO2005098029A2 (fr) * 2004-04-07 2005-10-20 Exiqon A/S Nouvelles methodes permettant de quantifier des micro arn et petits arn interferants
US7306904B2 (en) 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020679A1 (fr) * 1994-01-26 1995-08-03 Hybridon, Inc. Procede de detection de taux inferieurs a 10-9 d'oligonucleotides dans des fluides biologiques
US5770365A (en) 1995-08-25 1998-06-23 Tm Technologies, Inc. Nucleic acid capture moieties
WO1998004745A1 (fr) * 1996-07-31 1998-02-05 Mount Sinai School Of Medicine Of The City University Of New York Methode d'amplification des acides nucleiques: methode d'amplification avec signal d'hybridation (hsam)
US6355438B1 (en) 1999-11-12 2002-03-12 Isis Pharmaceuticals, Inc. Method for quantitating oligonucleotides
US7306904B2 (en) 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
WO2004085667A2 (fr) * 2003-03-24 2004-10-07 International Therapeutics, Inc. Techniques et compositions de detection de presence d'acides nucleiques dans un echantillon
WO2005098029A2 (fr) * 2004-04-07 2005-10-20 Exiqon A/S Nouvelles methodes permettant de quantifier des micro arn et petits arn interferants

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3699297A1 (fr) 2019-02-25 2020-08-26 QIAGEN GmbH Procédé permettant de déterminer le niveau d'un d'oligonucléotide antisens

Similar Documents

Publication Publication Date Title
Zhang et al. Detection of rare DNA targets by isothermal ramification amplification
USRE38960E1 (en) Isothermal strand displacement nucleic acid amplification
CN108368538B (zh) 用于生成邻近探针的方法
Mokany et al. MNAzyme qPCR with superior multiplexing capacity
AU2017328613A1 (en) Methods for performing multiplexed PCR
JP2021531778A (ja) 核酸検出方法
WO2011056933A1 (fr) Méthodes spécifiques de séquences pour la détection homogène et en temps réel de produits lamp
KR20090071641A (ko) 약 ８ 내지 ５０개 뉴클레오티드 길이의 짧은 핵산 서열의 정성적 및 정량적 검출을 위한 신규 방법
EP3574115A1 (fr) Procédé d'amplification exponentielle isotherme pour la détection d'acides nucléiques
EP3174998B1 (fr) Procédé de sélection d'une séquence d'acide nucléique cible
JP3909010B2 (ja) 高度ダイナミックレンジを有する定量的多重ｐｃｒ
US11655496B2 (en) Amplification of nucleic acids
CN102933720B (zh) 用于生成具有单链悬突的双链核酸的方法
CN105209640A (zh) 使用发卡寡核苷酸扩增核酸的方法
WO2019011875A1 (fr) Quantification d'oligonucleotides antisens (asos)
EP1793004B1 (fr) Procede de formation de polymere pour sonde de signal
Luo et al. Ultrasensitive sensing of T4 PNK phosphatase activity through establishing a novel transcription-based signal amplification platform
EP3682025A1 (fr) Nouveau procédé pour la génération de bibliothèques d'adn simple brin circulaire
WO2019053215A1 (fr) Stratégie d'hybridation-extension-ligature pour générer des banques d'adn simple brin circulaires
US20070122827A1 (en) Target nucleic acid signal detection
JP2023518217A (ja) 標的核酸を検出するためのループプライマー及びループ・デ・ループ方法
EP3496727A1 (fr) Constructions et procédés d'amplification de signaux.
EP3699297A1 (fr) Procédé permettant de déterminer le niveau d'un d'oligonucléotide antisens
JP2024506277A (ja) 脱塩基核酸を有する配列変換及びシグナル増幅ｄｎａ、並びにそれを使用する検出方法
KR20230063085A (ko) 분할된 t7 프로모터를 이용한 등온 단일 반응용 프로브 세트 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18735343

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18735343

Country of ref document: EP

Kind code of ref document: A1